Biodesix Inc (BDSX) FinancialsBDSXBiodesix Inc

Biodesix Inc (BDSX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lung Diagnostic Testing, accounting for 94.4% of total sales, equivalent to $25.35M. Another important revenue stream is Development Services. Understanding this composition is critical for investors evaluating how BDSX navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Biodesix Inc maintains a gross margin of 82.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -20.01%, while the net margin is -27.08%. These profitability ratios, combined with a Return on Equity (ROE) of -540.01%, provide a clear picture of how effectively BDSX converts its operational activities into shareholder value.

In the context of the broader market, BDSX competes directly with industry leaders such as XGN and AUNA. With a market capitalization of $226.72M, it holds a significant position in the sector. When comparing efficiency, BDSX's gross margin of 82.06% stands against XGN's 61.27% and AUNA's 35.72%. Such benchmarking helps identify whether Biodesix Inc is trading at a premium or discount relative to its financial performance.

Biodesix has demonstrated strong revenue growth, with Q2 2026 revenue at $26.9 million, a 34% increase year-over-year. The gross margin is also robust at 82.06%, reflecting efficient operations despite ongoing net losses.